Can I Take Melatonin with Praluent (Alirocumab)?

Why This Combination Raises Questions

Patients prescribed Praluent (alirocumab) for familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) often take over-the-counter supplements, and melatonin is among the most common. A 2022 CDC survey estimated that 27.2% of U.S. Adults used melatonin at least once in the prior 30 days [1]. When you are already injecting a biologic every two weeks, adding any pill naturally triggers concern about interactions.

The Core Question

The question is straightforward: does melatonin interfere with alirocumab's ability to lower LDL cholesterol, or does alirocumab change how melatonin works? The short answer is no on both counts. But the longer answer involves understanding why these two agents occupy entirely separate metabolic lanes.

Why Clinicians Still Want You to Disclose It

Even when a drug-supplement pair lacks a direct interaction, the combination can matter clinically. Melatonin influences glucose metabolism and cortisol rhythms. Patients on PCSK9 inhibitors frequently carry comorbid metabolic syndrome or type 2 diabetes. That overlap is where monitoring becomes relevant.

How Alirocumab Is Cleared from the Body

Alirocumab is a fully human IgG1 monoclonal antibody that binds circulating PCSK9 protein, preventing PCSK9 from degrading hepatic LDL receptors [2]. Understanding its clearance pathway explains why supplement interactions are rare.

Proteolytic Degradation, Not CYP Metabolism

Unlike small-molecule drugs (statins, ezetimibe, fibrates), monoclonal antibodies do not pass through cytochrome P450 enzymes in the liver. Alirocumab is broken down by the same proteolytic pathways that degrade endogenous immunoglobulins. Target-mediated drug disposition (TMDD) also contributes: once alirocumab binds PCSK9, the complex is internalized by hepatocytes and catabolized in lysosomes [2]. This means any supplement metabolized by CYP1A2, CYP3A4, CYP2C19, or other hepatic enzymes has no pharmacokinetic overlap with alirocumab.

Clinical Implication

Because the clearance mechanisms never intersect, melatonin cannot raise or lower alirocumab blood levels. The ODYSSEY OUTCOMES trial (N=18,924) did not exclude patients taking melatonin, and no signal of interaction-related adverse events appeared in the safety database [3].

How Melatonin Is Metabolized

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous hormone secreted by the pineal gland. Exogenous melatonin taken as a supplement follows a well-characterized hepatic clearance route.

CYP1A2 Is the Primary Enzyme

Roughly 90% of oral melatonin undergoes first-pass metabolism via CYP1A2 to 6-hydroxymelatonin, which is then sulfated and excreted renally [4]. A smaller fraction is metabolized by CYP2C19. Oral bioavailability is low (approximately 15%), and the plasma half-life is 20 to 50 minutes for immediate-release formulations [4].

What Could Theoretically Alter Melatonin Levels

CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) can increase melatonin exposure significantly. CYP1A2 inducers (smoking, heavy caffeine intake) can reduce it. Alirocumab is neither an inhibitor nor an inducer of any CYP enzyme. It does not even enter hepatocyte cytoplasm in a way that would affect enzyme transcription.

Bottom Line on Pharmacokinetics

There is no mechanistic basis for a pharmacokinetic interaction between these two agents. The FDA-approved Praluent prescribing information does not list melatonin or any dietary supplement as a contraindicated co-administration [5]. The Natural Medicines Comprehensive Database similarly assigns no interaction rating to this pair.

The Pharmacodynamic Angle: Glucose and Metabolic Effects

While there is no pharmacokinetic conflict, a pharmacodynamic consideration exists. It is modest but worth understanding for patients who carry metabolic risk factors.

Melatonin and Glucose Tolerance

A randomized, double-blind crossover study by Rubio-Sastre et al. (2014, N=21 healthy women) found that a single 5 mg dose of melatonin taken before an oral glucose tolerance test impaired glucose clearance and reduced insulin sensitivity by approximately 12% compared to placebo [6]. The MTNR1B gene variant rs10830963, carried by roughly 30% of Europeans, amplifies this effect. A genome-wide association study published in Nature Genetics identified this variant as a diabetes risk locus linked to melatonin receptor signaling in pancreatic beta cells [7].

Why This Matters for Praluent Patients

Patients prescribed alirocumab often have comorbid conditions. In the ODYSSEY OUTCOMES trial, 28.8% of participants had type 2 diabetes at baseline, and another 19.5% had prediabetes [3]. If you are in that metabolic risk category and take melatonin nightly at doses of 5 mg or above, a small but additive glucose-impairing effect could be clinically meaningful over months.

What the Data Does Not Show

No published study has demonstrated that melatonin worsens cardiovascular outcomes in patients on PCSK9 inhibitors. The glucose effect is transient, dose-dependent, and most pronounced when melatonin is taken close to meals. Taking melatonin at bedtime, at least 2 hours after your last meal, largely mitigates this concern.

Dose-Separation and Practical Timing

Because there is no pharmacokinetic interaction, rigid dose-separation windows are not necessary. Practical timing recommendations exist for patient comfort and to minimize any glucose-related pharmacodynamic overlap.

Alirocumab Injection Timing

Alirocumab 75 mg or 150 mg is injected subcutaneously every 14 days. The injection can be given at any time of day. Peak serum concentration (Cmax) is reached in 3 to 7 days, and the half-life is 17 to 20 days at steady state [5]. The injection site (abdomen, thigh, or upper arm) does not affect absorption kinetics meaningfully.

Melatonin Timing

Take melatonin 30 to 60 minutes before your intended sleep time. Doses of 0.5 to 3 mg are sufficient for most adults to shift circadian phase. A 2013 meta-analysis of 19 RCTs (N=1,683) found that melatonin reduced sleep onset latency by 7.06 minutes (95% CI: 4.37 to 9.75) and increased total sleep time by 8.25 minutes compared to placebo [8].

Suggested Routine

On injection days, administer alirocumab at your usual time (morning or evening). Take melatonin at bedtime as you normally would. No special spacing is required. If you prefer simplicity, inject alirocumab in the morning and take melatonin at night. That natural separation of 12+ hours provides psychological reassurance even though it is not pharmacologically necessary.

Monitoring Recommendations

Even in the absence of a direct interaction, good clinical practice calls for monitoring when combining any biologic with a supplement taken daily.

Lipid Panel

Continue your standard lipid monitoring schedule. The Endocrine Society and the 2018 AHA/ACC cholesterol guideline recommend checking LDL-C 4 to 12 weeks after initiating alirocumab, then every 3 to 12 months [9]. Melatonin should not alter these values, but confirming that LDL-C remains at target (<70 mg/dL for very high-risk ASCVD, <55 mg/dL per ESC/EAS 2019 guidelines) is standard care regardless of supplementation [10].

Fasting Glucose and HbA1c

If you take melatonin nightly at doses of 3 mg or more, ask your clinician to check fasting glucose and HbA1c at baseline and every 6 months. This is especially relevant if you have prediabetes (HbA1c 5.7-6.4%) or established type 2 diabetes.

Injection-Site Reactions

Alirocumab injection-site reactions occurred in 7.2% of patients in ODYSSEY OUTCOMES versus 5.8% on placebo [3]. Melatonin does not affect injection-site tolerability. If you notice redness, swelling, or itching at the injection site, report it to your prescriber. It is unrelated to melatonin.

Sleep Quality Tracking

A practical but often overlooked monitoring point: if you started melatonin because of poor sleep, track whether alirocumab injection nights disrupt your routine. Some patients report mild fatigue or malaise after injections. Knowing your baseline sleep architecture (via a simple sleep diary or wearable tracker) helps distinguish injection-related effects from melatonin efficacy.

Melatonin's Potential Cardiovascular Effects

A secondary reason patients on PCSK9 inhibitors ask about melatonin is curiosity about whether melatonin itself offers cardiovascular benefit. Some preliminary data exists, though it is far from definitive.

Antioxidant and Anti-Inflammatory Properties

Melatonin is a potent free-radical scavenger. A 2020 systematic review of 12 RCTs (N=632) found that melatonin supplementation reduced C-reactive protein (CRP) by a weighted mean difference of -1.96 mg/L (95% CI: -2.84 to -1.08) [11]. CRP is a marker of systemic inflammation associated with atherosclerosis progression.

Lipid Effects in Small Trials

A randomized controlled trial by Goyal et al. (2014, N=30 patients with metabolic syndrome) reported that 5 mg melatonin nightly for 2 months reduced LDL-C by 11.1% compared to placebo [12]. These results have not been replicated in larger populations, and the mechanism (possibly via upregulation of LDL receptor expression) remains speculative.

What This Means Practically

Do not take melatonin as a lipid-lowering agent. Alirocumab produces a 50 to 60% reduction in LDL-C. Any additive LDL-lowering from melatonin would be marginal and unreliable. Use melatonin for sleep. Use alirocumab for cholesterol. They serve different purposes.

Special Populations

Older Adults (65+)

Melatonin clearance decreases with age because CYP1A2 activity declines. Older adults may experience more morning grogginess or prolonged sedation. Start at 0.5 mg. Alirocumab pharmacokinetics are not significantly altered by age according to population PK analyses from the ODYSSEY program [5].

Patients on Statins

Most alirocumab patients are co-prescribed a maximally tolerated statin. Atorvastatin and rosuvastatin are metabolized by CYP3A4 and CYP2C9, respectively. Melatonin (CYP1A2) does not compete with either statin's metabolic pathway. The triple combination of statin + alirocumab + melatonin carries no identified pharmacokinetic concern.

Patients Taking Fluvoxamine

Fluvoxamine is a strong CYP1A2 inhibitor. If you take fluvoxamine for OCD or depression, melatonin plasma levels can rise dramatically. One pharmacokinetic study showed a 17-fold increase in melatonin AUC with fluvoxamine co-administration [13]. This is a melatonin-fluvoxamine interaction, not an alirocumab interaction, but it deserves mention because the resulting high melatonin exposure could amplify glucose effects. Discuss dosing with your prescriber.

Pregnancy and Lactation

Alirocumab is pregnancy category X in the context of statin co-therapy. Melatonin lacks adequate human pregnancy data. Neither agent should be assumed safe during pregnancy without explicit clinician guidance.

What to Do If You Are Already Taking Both

If you have been taking melatonin and Praluent together without problems, there is no reason to stop either one. Review these three checkpoints with your clinician at your next visit:

1. Confirm your LDL-C is at guideline-directed target.
2. Check fasting glucose and HbA1c if you have metabolic risk factors and are taking melatonin at 3 mg or above nightly.
3. Report any new symptoms (excessive daytime sleepiness, mood changes, injection-site worsening) so they can be attributed correctly.

The American College of Cardiology's 2018 guideline on blood cholesterol management states: "Clinicians should routinely ask about dietary supplements and document them, even when no interaction is expected, because patterns may emerge in post-marketing surveillance" [9].

When to Contact Your Prescriber

Stop melatonin and call your prescriber if you experience any of the following while on alirocumab:

• Persistent morning confusion or excessive sedation lasting past noon
• New-onset hyperglycemia (fasting glucose repeatedly above 126 mg/dL in a previously normoglycemic patient)
• Allergic reaction signs: facial swelling, difficulty breathing, widespread rash (these would more likely be alirocumab-related, occurring in <1% of patients [5])
• Severe injection-site reaction (necrosis, ulceration)

Melatonin at standard doses (0.5-5 mg) has an excellent safety profile. A Cochrane review of melatonin for sleep disorders found no serious adverse events across 37 included studies [14]. The concern here is not that the combination is dangerous. It is that correct attribution of new symptoms requires knowing exactly what you are taking.